Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab for Macular Edema in Vein Occlusions (LVO)
NCT00407355Phase 2Completed
- Sponsor
- Peter A Campochiaro
- Start
- Jan 2006
- Primary completion
- Feb 2013
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in macular edema (2 arms), sponsored by Peter A Campochiaro. Primary endpoints: Best Corrected Visual Acuity Change From Baseline at 72 months and Retinal Thickness Change From Baseline at 72 months. Started Jan 2006; status: completed.
02
Drugs
ranibizumab
03
Conditions
macular edema
Beyond the preview
Go deeper on NCT00407355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00407355.